Search

Your search keyword '"Radinov, A."' showing total 20 results
Start Over Author "Radinov, A." Publisher elsevier bv
20 results on '"Radinov, A."'

1. Prognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma

Author

Zhanet Grudeva-Popova, D. Tumbeva, G. Tzvetkova, Emil Spasov, B. Spasov, P. Ganeva, L. Gercheva, R. Petrova, I. Micheva, Nikolai Tz. Tzvetkov, Lachezar H. Bogdanov, E. Hadzhiev, Vesselina Goranova-Marinova, K. Ignatova, G. Arnaudov, and A. Radinov

Subjects
Oncology, medicine.medical_specialty, Hematology, business.industry, medicine.medical_treatment, Hematopoietic stem cell transplantation, medicine.disease, Lymphoma, Transplantation, Autologous stem-cell transplantation, Nodular sclerosis, Internal medicine, medicine, Progression-free survival, Brentuximab vedotin, business, medicine.drug
Abstract

Background Brentuximab Vedotin (BV) treatment has improved the prognosis and survival of patients with Hodgkin’s lymphoma, relapsed after stem cell transplantation or having refractory disease. Aim: To analyze the prognostic factors, influencing the outcome after therapy with BV in relapsed or refractory patients with Hodgkin’s lymphoma. Methods We studied sixty-four (64) Hodgkin’s lymphoma patients treated with BV in six Hematology clinics in Bulgaria. The male / female ratio was 1 / 1, the mean age at the time of BV therapy was 40.66+/-13.1 years. The most common histological variant was nodular sclerosis 46 (71.9%). In the II clinical stage there were 26 patients (40.6%), in IIIrd - 17 (26.6%), in IVth - 21 (32.8%). All patients before treatment with BV received median of 4 (2-12) treatment lines, 30 ( 46.9%) received =/>3 lines. Autologous stem cell transplantation (autoSCT) was performed in 45 (70.3%) patients, two of which were second autologous SCTs, and in one auto/ allo SCT. Results ORR was 60.9% (N = 39). Complete response was achieved in 39.1% (25) and partial response in 21.9% (14) patients. Stable disease was registered in 10.9% (7) and progression in 28.1% (18). PFS for the entire group was 14 months. The median survival (MS) was not reached by the end of the analysis. At least partial therapeutic response was significantly higher in patients with chemosensitive disease before autoSCT ( P = 0.006, R = +0.340), these who have undergone autoSCT ( P = 0.021, R= -0.335) and when BV was started as consolidation therapy by month 3 after autoSCT ( P = 0.02, R = +0.287). The only significant prognostic factor that determines a remarkably longer EFS is the type of therapeutic response itself: in the CR + PR group, the median PFS is not reached by the time of the analysis, while in patients with stable disease and progression EFS is 7 months (P Conclusions BV is most effective in patients with chemosensitive disease, and when used as consolidation therapy early, by 3-rd month after autoSCT. Our results confirm the international experience. BV improves the therapeutic response and prolongs progression-free survival in the patients with Hodgkin’s lymphoma who previously had really bad prognosis. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

Published
2019

2. Prognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma

Author

Goranova-Marinova, V.S., primary, Ignatova, K., additional, Ganeva, P., additional, Spasov, E., additional, Arnaudov, G., additional, Micheva, I., additional, Gercheva, L., additional, Radinov, A., additional, Petrova, R., additional, Tzvetkova, G., additional, Hadzhiev, E., additional, Bogdanov, L., additional, Tzvetkov, N., additional, Spasov, B., additional, Grudeva-Popova, Z., additional, and Tumbeva, D., additional

Published
2019
Full Text
View/download PDF

3. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

Author

Mullane, Kathleen M, primary, Morrison, Vicki A, additional, Camacho, Luis H, additional, Arvin, Ann, additional, McNeil, Shelly A, additional, Durrand, Jessie, additional, Campbell, Bernadette, additional, Su, Shu-Chih, additional, Chan, Ivan S F, additional, Parrino, Janie, additional, Kaplan, Susan S, additional, Popmihajlov, Zoran, additional, Annunziato, Paula W, additional, Cerana, S, additional, Dictar, MO, additional, Bonvehi, P, additional, Tregnaghi, JP, additional, Fein, L, additional, Ashley, D, additional, Singh, M, additional, Hayes, T, additional, Playford, G, additional, Morrissey, O, additional, Thaler, J, additional, Kuehr, T, additional, Greil, R, additional, Pecherstorfer, M, additional, Duck, L, additional, Van Eygen, K, additional, Aoun, M, additional, De Prijck, B, additional, Franke, FA, additional, Barrios, CHE, additional, Mendes, AVA, additional, Serrano, SV, additional, Garcia, RF, additional, Moore, F, additional, Camargo, JFC, additional, Pires, LA, additional, Alves, RS, additional, Radinov, A, additional, Oreshkov, K, additional, Minchev, V, additional, Hubenova, AI, additional, Koynova, T, additional, Ivanov, I, additional, Rabotilova, B, additional, Petrov, PA, additional, Chilingirov, P, additional, Karanikolov, S, additional, Raynov, J, additional, Grimard, D, additional, McNeil, S, additional, Kumar, D, additional, Larratt, LM, additional, Weiss, K, additional, Delage, R, additional, Diaz-Mitoma, FJ, additional, Cano, PO, additional, Couture, F, additional, Carvajal, P, additional, Yepes, A, additional, Torres Ulloa, R, additional, Fardella, P, additional, Caglevic, C, additional, Rojas, C, additional, Orellana, E, additional, Gonzalez, P, additional, Acevedo, A, additional, Galvez, KM, additional, Gonzalez, ME, additional, Franco, S, additional, Restrepo, JG, additional, Rojas, CA, additional, Bonilla, C, additional, Florez, LE, additional, Ospina, AV, additional, Manneh, R, additional, Zorica, R, additional, Vrdoljak, DV, additional, Samarzija, M, additional, Petruzelka, L, additional, Vydra, J, additional, Mayer, J, additional, Cibula, D, additional, Prausova, J, additional, Paulson, G, additional, Ontaneda, M, additional, Palk, K, additional, Vahlberg, A, additional, Rooneem, R, additional, Galtier, F, additional, Postil, D, additional, Lucht, F, additional, Laine, F, additional, Launay, O, additional, Laurichesse, H, additional, Duval, X, additional, Cornely, OA, additional, Camerer, B, additional, Panse, J, additional, Zaiss, M, additional, Derigs, H-G, additional, Menzel, H, additional, Verbeek, M, additional, Georgoulias, V, additional, Mavroudis, D, additional, Anagnostopoulos, A, additional, Terpos, E, additional, Cortes, D, additional, Umanzor, J, additional, Bejarano, S, additional, Galeano, RW, additional, Wong, RSM, additional, Hui, P, additional, Pedrazzoli, P, additional, Ruggeri, L, additional, Aversa, F, additional, Bosi, A, additional, Gentile, G, additional, Rambaldi, A, additional, Contu, A, additional, Marei, L, additional, Abbadi, A, additional, Hayajneh, W, additional, Kattan, J, additional, Farhat, F, additional, Chahine, G, additional, Rutkauskiene, J, additional, Marfil Rivera, LJ, additional, Lopez Chuken, YA, additional, Franco Villarreal, H, additional, Lopez Hernandez, J, additional, Blacklock, H, additional, Lopez, RI, additional, Alvarez, R, additional, Gomez, AM, additional, Quintana, TS, additional, Moreno Larrea, MDC, additional, Zorrilla, SJ, additional, Alarcon, E, additional, Samanez, FCA, additional, Caguioa, PB, additional, Tiangco, BJ, additional, Mora, EM, additional, Betancourt-Garcia, RD, additional, Hallman-Navarro, D, additional, Feliciano-Lopez, LJ, additional, Velez-Cortes, HA, additional, Cabanillas, F, additional, Ganea, DE, additional, Ciuleanu, TE, additional, Ghizdavescu, DG, additional, Miron, L, additional, Cebotaru, CL, additional, Cainap, CI, additional, Anghel, R, additional, Dvorkin, MV, additional, Gladkov, OA, additional, Fadeeva, NV, additional, Kuzmin, AA, additional, Lipatov, ON, additional, Zbarskaya, II, additional, Akhmetzyanov, FS, additional, Litvinov, IV, additional, Afanasyev, BV, additional, Cherenkova, M, additional, Lioznov, D, additional, Lisukov, IA, additional, Smirnova, YA, additional, Kolomietz, S, additional, Halawani, H, additional, Goh, YT, additional, Drgona, L, additional, Chudej, J, additional, Matejkova, M, additional, Reckova, M, additional, Rapoport, BL, additional, Szpak, WM, additional, Malan, DR, additional, Jonas, N, additional, Jung, CW, additional, Lee, DG, additional, Yoon, SS, additional, Lopez Jimenez, J, additional, Duran Martinez, I, additional, Rodriguez Moreno, JF, additional, Solano Vercet, C, additional, de la Camara, R, additional, Batlle Massana, M, additional, Yeh, S-P, additional, Chen, C-Y, additional, Chou, H-H, additional, Tsai, C-M, additional, Chiu, C-H, additional, Siritanaratkul, N, additional, Norasetthada, L, additional, Sriuranpong, V, additional, Seetalarom, K, additional, Akan, H, additional, Dane, F, additional, Ozcan, MA, additional, Ozsan, GH, additional, Kalayoglu Besisik, SF, additional, Cagatay, A, additional, Yalcin, S, additional, Peniket, A, additional, Mullan, SR, additional, Dakhil, KM, additional, Sivarajan, K, additional, Suh, JJ-G, additional, Sehgal, A, additional, Marquez, F, additional, Gomez, EG, additional, Mullane, MR, additional, Skinner, WL, additional, Behrens, RJ, additional, Trevarthe, DR, additional, Mazurczak, MA, additional, Lambiase, EA, additional, Vidal, CA, additional, Anac, SY, additional, Rodrigues, GA, additional, Baltz, B, additional, Boccia, R, additional, Wertheim, MS, additional, Holladay, CS, additional, Zenk, D, additional, Fusselman, W, additional, Wade III, JL, additional, Jaslowsk, AJ, additional, Keegan, J, additional, Robinson, MO, additional, Go, RS, additional, Farnen, J, additional, Amin, B, additional, Jurgens, D, additional, Risi, GF, additional, Beatty, PG, additional, Naqvi, T, additional, Parshad, S, additional, Hansen, VL, additional, Ahmed, M, additional, Steen, PD, additional, Badarinath, S, additional, Dekker, A, additional, Scouros, MA, additional, Young, DE, additional, Graydon Harker, W, additional, Kendall, SD, additional, Citron, ML, additional, Chedid, S, additional, Posada, JG, additional, Gupta, MK, additional, Rafiyath, S, additional, Buechler-Price, J, additional, Sreenivasappa, S, additional, Chay, CH, additional, Burke, JM, additional, Young, SE, additional, Mahmood, A, additional, Kugler, JW, additional, Gerstner, G, additional, Fuloria, J, additional, Belman, ND, additional, Geller, R, additional, Nieva, J, additional, Whittenberger, BP, additional, Wong, BMY, additional, Cescon, TP, additional, Abesada-Terk, G, additional, Guarino, MJ, additional, Zweibach, A, additional, Ibrahim, EN, additional, Takahashi, G, additional, Garrison, MA, additional, Mowat, RB, additional, Choi, BS, additional, Oliff, IA, additional, Singh, J, additional, Guter, KA, additional, Ayrons, K, additional, Rowland, KM, additional, Noga, SJ, additional, Rao, SB, additional, Columbie, A, additional, Nualart, MT, additional, Cecchi, GR, additional, Campos, LT, additional, Mohebtash, M, additional, Flores, MR, additional, Rothstein-Rubin, R, additional, O'Connor, BM, additional, Soori, G, additional, Knapp, M, additional, Miranda, FG, additional, Goodgame, BW, additional, Kassem, M, additional, Belani, R, additional, Sharma, S, additional, Ortiz, T, additional, Sonneborn, HL, additional, Markowitz, AB, additional, Wilbur, D, additional, Meiri, E, additional, Koo, VS, additional, Jhangiani, HS, additional, Wong, L, additional, Sanani, S, additional, Lawrence, SJ, additional, Jones, CM, additional, Murray, C, additional, Papageorgiou, C, additional, Gurtler, JS, additional, Ascensao, JL, additional, Venigalla, ML, additional, D'Andrea, M, additional, De Las Casas, C, additional, Haile, DJ, additional, Qazi, FU, additional, Santander, JL, additional, Thomas, MR, additional, Rao, VP, additional, Craig, M, additional, Garg, RJ, additional, Robles, R, additional, Lyons, RM, additional, Stegemoller, RK, additional, Goel, S, additional, Garg, S, additional, Lowry, P, additional, Lynch, C, additional, Lash, B, additional, Repka, T, additional, Baker, J, additional, Goueli, BS, additional, Campbell, TC, additional, Van Echo, DA, additional, Lee, YJ, additional, Reyes, EA, additional, Senecal, FM, additional, Donnelly, G, additional, Byeff, P, additional, Weiss, R, additional, Reid, T, additional, Roeland, E, additional, Goel, A, additional, Prow, DM, additional, Brandt, DS, additional, Kaplan, HG, additional, Payne, JE, additional, Boeckh, MG, additional, Rosen, PJ, additional, Mena, RR, additional, Khan, R, additional, Betts, RF, additional, Sharp, SA, additional, Morrison, VA, additional, Fitz-Patrick, D, additional, Congdon, J, additional, Erickson, N, additional, Abbasi, R, additional, Henderson, S, additional, Mehdi, A, additional, Wos, EJ, additional, Rehmus, E, additional, Beltzer, L, additional, Tamayo, RA, additional, Mahmood, T, additional, Reboli, AC, additional, Moore, A, additional, Brown, JM, additional, Cruz, J, additional, Quick, DP, additional, Potz, JL, additional, Kotz, KW, additional, Hutchins, M, additional, Chowhan, NM, additional, Devabhaktuni, YD, additional, Braly, P, additional, Berenguer, RA, additional, Shambaugh, SC, additional, O'Rourke, TJ, additional, Conkright, WA, additional, Winkler, CF, additional, Addo, FEK, additional, Duic, JP, additional, High, KP, additional, Kutner, ME, additional, Collins, R, additional, Carrizosa, DR, additional, Perry, DJ, additional, Kailath, E, additional, Rosen, N, additional, Sotolongo, R, additional, Shoham, S, additional, and Chen, T, additional

Published
2019
Full Text
View/download PDF

4. Selective palladium-catalyzed hydrogenolysis of a secondary propargylic alcohol in the synthesis of vitamin D analog Ro 23–7553: substrate and ligand control

Author

Roumen Nikolaev Radinov and Stanley D. Hutchings

Subjects
chemistry.chemical_classification, Steric effects, Ligand, Stereochemistry, Allene, Organic Chemistry, Alkyne, chemistry.chemical_element, Biochemistry, Medicinal chemistry, chemistry.chemical_compound, chemistry, Hydrogenolysis, Drug Discovery, Propargyl, Phosphine, Palladium
Abstract

Selective palladium-catalyzed hydrogenolysis of propargylic alcohol 9, via its formate 10 or carbonate 13, gave up to 98% of alkyne 11. Alkyne allene selectivity is controlled by the steric bulk of the phosphine ligand, as well as the propargylic (C-22) and alkyne (C-24) substituents in the substrate. A steric ligand-substrate interaction in the intermediate π- propargyl allenyl palladium complexes is suggested to explain these effects.

Published
1999

6. 1,3 acyclic control in free radical reactions: Threo—selective additions

Author

Andrew T. McPhail, Christopher L. Mero, Ned A. Porter, and Rumen Radinov

Subjects
chemistry.chemical_classification, Addition reaction, Chemistry, Organic Chemistry, Drug Discovery, Organic chemistry, Biochemistry, Alkyl
Abstract

Summary Oxazolidinone acrylamides undergo addition reactions with alkyl iodides and allyltributylstannane to give 1,3-substituted products with a threo preference in excess of 10:1. This threo preference is highest for reactions carried out in nonpolar solvents, a result consistent with dipolar stabilization of the transition state leading to the threo product.

Published
1995

7. Excited state properties of 10-phenyl-benzo[b][1,6]naphthyridines in solution

Author

Rumen N. Radinov, Peter Nikolov, and Helmut Görner

Subjects
Intersystem crossing, Chemistry, General Chemical Engineering, Excited state, General Physics and Astronomy, Quantum yield, General Chemistry, Singlet state, Triplet state, Solvent effects, Photochemistry, Phosphorescence, Fluorescence
Abstract

The relaxation pathways of excited 10-phenyl-benzo[b][1,6]naphthyridine (PN), an analogue of acridine, and a series of 12 derivatives (R-6: CF3, Br, Cl, F, CH3, OCH3; R-8: SO2NH2, Br, Cl, CH3, OCH3, OC2H5) were studied in several solvents at 297 and 77 K. Fluorescence, intersystem crossing and photodecomposition processes were examined by stationary and transient techniques. At 297 K, the quantum yield of fluorescence (φf) increases significantly with solvent polarity and with electron-donating substitution, intersystem crossing partly compensating this effect. The triplet is characterized by TT absorption at 297 and 77 K and by phosphorescence at 77 K. Generally, intersystem crossing is less sensitive to environment and substitution than φf. Photodecomposition is negligible for PNs in acetonitrile at room temperature, but effective for PN and most of its R-8 derivatives in alcohols, e.g. 2-propanol, ethanol or methanol. This is ascribed to photoreduction, involving a spectroscopically hidden, probably ( n , π ∗ ) singlet state.

Published
1995

8. Enantioselective addition of (Z)- and (E)-alkenylzinc bromides to aldehydes: asymmetric synthesis of sec-allylalcohols

Author

Rumen N. Radinov and Wolfgang Oppolzer

Subjects
chemistry.chemical_classification, chemistry, ddc:540, Organic Chemistry, Drug Discovery, Enantioselective synthesis, Organic chemistry, Methylephedrine, Aliphatic compound, Enantiomeric excess, Biochemistry, Aldehyde, Medicinal chemistry
Abstract

In situ prepared ( Z )- and ( E )-1-alkenylzinc bromides 5 were added to various aldehydes 1 in the presence of lithiated (+)- N -methylephedrine or (+)-2-( N,N -dimethylamino)-1,2-diphenylethanol to give sec . allyalcohols 7 in high optical purity with simple recovery of the chiral aminol 6 .

Published
1991

9. Red-Al® reduction of 4-silyloxy propargylic alcohols. A surprising round trip for the silyl group

Author

Errol Sheldon Schnurman and Roumen Nikolaev Radinov

Subjects
Allylic rearrangement, Stereospecificity, chemistry, Silylation, Group (periodic table), Organic Chemistry, Drug Discovery, chemistry.chemical_element, Organic chemistry, Biochemistry, Oxygen, Medicinal chemistry
Abstract

The Red-Al ® reduction of 4-silyloxy propargylic alcohols to 4-silyloxy allylic alcohols involves two consecutive regio- and stereospecific 1,3 silyl migrations — from oxygen to carbon and then back to the original oxygen.

Published
1999

17. Enantioselective synthesis of sec-allylalcohols by catalytic asymmetric addition of divinylzinc to aldehydes

Author

Wolfgang Oppolzer and Rumen N. Radinov

Subjects
chemistry.chemical_classification, Addition reaction, Reaction mechanism, Denticity, Stereochemistry, organic chemicals, Organic Chemistry, Enantioselective synthesis, chemistry.chemical_element, Zinc, Biochemistry, Aldehyde, Medicinal chemistry, Catalysis, Benzaldehyde, chemistry.chemical_compound, chemistry, Drug Discovery, heterocyclic compounds
Abstract

Readily available chiral tridentate ligand 8 catalyzes the highly Si-face selective addition of diethyl-, di-n-propylzinc and, more significantly, of divinylzinc to aromatic and aliphatic aldehydes whereas bidentate ligands 11 and 12 exert a topologically reversed catalytic bias.

Published
1988

18. 3-Phenylpyrazolo(4,3-c)pyridine and derivatives: structure determination

Author

Marietta Haimova, Svetlana Simova, Allia Tadjer, Ekaterina Simova, and Rumen Radinov

Subjects
Inorganic Chemistry, CNDO/2, chemistry.chemical_compound, Uv spectra, chemistry, Computational chemistry, Organic Chemistry, Pyridine, Physical chemistry, Carbon-13 NMR, Tautomer, Spectroscopy, Analytical Chemistry
Abstract

The structures of 3-phenylpyrazolo(4,3-c)pyridine (1) and 5-methyl-3-phenyl-4,5,6,7-tetrahydropyrazolo(4,3-c)pyridine (2) are determined by detailed 1H and 13C NMR analysis and theoretical calculations in comparison with their N-methyl derivatives as fixed models. CNDO/2 and PPP calculations are performed on the three prototropic forms admissible for the tautomeric system 1. By comparison of the 13C NMR and UV spectra of 1 with those of its three fixed N-methyl derivatives and of the UV spectra calculated for the tautomers of 1 with that experimentally obtained in the range 200–450 nm, 3-phenylpyrazolo(4,3-c)pyridine (1) is established to exist entirely in the 1H tautomeric form 1A. By 13C NMR investigations of 5-methyl-3-phenyl-4,5,6,7-tetrahydropyrazolo(4,3-c)-pyridine (2), in comparison with its fixed 1-methyl-1H derivative 9 and other substituted pyrazoles, 2 is determined to be a mixture of the 1H- (2A) and 2H- (2B) tautomers with 2A largely predominating. The compounds investigated are described here for the first time.

Published
1987

Catalog

Books, media, physical & digital resources
See catalog results